Sales & Earnings In Brief
This article was originally published in The Tan Sheet
Executive Summary
GSK: Consumer Healthcare sales grew 5% to $1.5 bil. during the second quarter of 2006, GlaxoSmithKline announces July 26. Revenues in European and International markets increased 8% and 9%, respectively, while sales in North America declined 3%, which reflected, in part, the impact of divesting several dermatological creams in 2005. OTC drug sales grew 3% to $674 mil. during the quarter as a result of sales growth in analgesics (13%), smoking cessation products (8%) and respiratory tract medicines (10%). Oral care sales grew 7% to $467 mil. due to a 25% revenue growth for Sensodyne, which offset the 5% reduction in Aquafresh sales...
|
GSK: Consumer Healthcare sales grew 5% to $1.5 bil. during the second quarter of 2006, GlaxoSmithKline announces July 26. Revenues in European and International markets increased 8% and 9%, respectively, while sales in North America declined 3%, which reflected, in part, the impact of divesting several dermatological creams in 2005. OTC drug sales grew 3% to $674 mil. during the quarter as a result of sales growth in analgesics (13%), smoking cessation products (8%) and respiratory tract medicines (10%). Oral care sales grew 7% to $467 mil. due to a 25% revenue growth for Sensodyne , which offset the 5% reduction in Aquafresh sales.... Schering-Plough: Sales of OTC Claritin decreased by $22 mil. (16%) to $111 mil. in the second quarter compared to the year-ago period, primarily due to lower sales of Claritin-D , Schering-Plough announces July 24. Claritin-D, which contains pseudoephedrine, was negatively affected by continued retail restrictions on the decongestant. Global sales for the follow-on Rx drug Clarinex (desloratadine) were $226 mil., up 10%, the firm reports. Sales for the consumer division were $349 mil., up 5% versus the second quarter of 2005. Schering notes that it has entered the fourth year of its six- to eight-year action agenda announced in April 2003. Key actions in the second quarter included the streamlining of the global supply chain by phasing out manufacturing operations in Puerto Rico (1 'The Tan Sheet' June 5, 2006, In Brief).... NBTY: Net sales for the fiscal third quarter (ended June 30) increased by 8% ($36 mil.) to $475 mil., NBTY announces July 27. Revenues were once again driven by the Solgar brand of vitamins, which generated $24 mil. during the quarter. The brand was acquired from Wyeth Consumer Healthcare in 2005 (2 (Also see "NBTY “Tough Quarter” Caused By Vitamin E Sales, Stalled Market - Rudolph" - Pink Sheet, 8 Aug, 2005.), p. 9). Net income for the quarter was $30 mil., or $0.43 per diluted share, compared to $16 mil., or $0.23 per diluted share, in the prior-year period. The company's strong financial position has allowed for accelerated repayment of $206 mil. of long-term debt during the first nine months of fiscal 2006 and an additional payment of $10 mil. during the third quarter.... Nutraceutical: Net sales for the fiscal 2006 third quarter were flat at $37 mil., Nutraceutical International Corporation announces July 27. The Solaray marketer, which is involved in a federal lawsuit regarding FDA's 2004 ephedra ban, reported net income levels of $3.4 mil ($0.29 diluted earnings per share), compared to $3.2 mil. ($0.27 diluted earnings per share), for the same quarter of fiscal 2005. The firm showed "positive improvements in operating margins as we further integrated our manufacturing processes in our recently purchased facility," CEO Bill Gay says.... |